Skip to content


  • Poster presentation
  • Open Access

In the NHS breast screening programme does radiographer-reported clinical history add value to mammography?

  • 1,
  • 1 and
  • 1
Breast Cancer Research200911 (Suppl 2) :P11

  • Published:


  • Breast Cancer
  • Clinical History
  • Invasive Breast Cancer
  • Frequent Symptom
  • Common Complaint


Currently, all women attending breast screening are asked by radiographers about breast symptoms. Recording and assessing these responses takes time. We have studied the usefulness of this practice. No group that we are aware of have validated this since the routine use of two-view mammography.


In our region, 40,204 women were screened over a 22-month period. All responses from the 703 (1.7%) women reporting breast symptoms were analysed and films reviewed from all cancers detected in this group.


The commonest complaints were pain 386 (55%) or a lump 163 (23%). Less frequent symptoms included skin and nipple changes. Of the symptomatic women, 157 (22%) were recalled for assessment. More women complaining of a lump were recalled (58%) than those reporting skin changes (39%) or pain (7%).

From those recalled, 23 cancers were diagnosed, of which 14 were in women reporting a lump. Out of the 23 cancers, 21 had M4/M5 mammographic abnormalities (91%). Two women with cancer had normal screening mammograms but were recalled due to their clinical history. The first patient reported a lump. The second clinical recall was due to an asymptomatic skin dimple noticed by the radiographer. Both clinical abnormalities corresponded to invasive breast cancers.


Of the 40,204 women screened, 2 (<0.0001%) had cancer diagnosed following a clinical history recall with normal screening mammograms. This is a low yield and questions how useful the clinical history is, given the extra time and resources required for assessment.

Authors’ Affiliations

Primrose Breast Care Unit, Derriford Hospital, Plymouth, Devon, UK


© Currie et al; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd.